4.7 Article

Development of High-Level Daptomycin Resistance in Abiotrophia and Granulicatella Species Isolates from Patients with Infective Endocarditis

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 10, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02522-20

Keywords

A. defectiva; G. adiacens; HLDR; daptomycin; synergy; bactericidal activity; in vitro; infective endocarditis

Funding

  1. Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Madrid (Spain) [PI17/01251]
  2. Spanish Network for Research in Infectious Diseases [REIPI RD06/0008]
  3. Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
  4. Instituto Carlos III [CM17/00062]
  5. Ministerio de Economia y Competitividad, Madrid (Spain) [CM17/00062]
  6. European Regional Development Fund (ERDF) A Way To Build Europe
  7. Lundbeck Foundation [R288-2018-1898]
  8. Hospital Clinic, Barcelona, Spain

Ask authors/readers for more resources

This study is the first to demonstrate rapid development of high-level daptomycin resistance in Abiotrophia and Granulicatella species in vitro. The resistance was stable, and most combination therapies did not prevent its development.
Abiotrophia and Granulicatella species are fastidious organisms, representing the causative agents of;1% to 3% of cases of infective endocarditis (IE). Little is known about the optimal antibiotic treatment for these species, and daptomycin has been suggested as a therapeutic option. We describe the antimicrobial profiles of Abiotrophia and Granulicatella IE isolates, investigate high-level daptomycin resistance (HLDR) development, and evaluate daptomycin activity in combination therapy. In vitro studies with 16 IE strains (6 Abiotrophia defectiva strains, 9 Granulicatella adiacens strains, and 1 G. elegans strain) were performed using microdilution to determine MICs and time-kill methodology to evaluate combination therapy. Daptomycin nonsusceptibility (DNS) (MIC >= 2 mg/liter) and HLDR (MIC >= 256 mg/liter) were based on existing Clinical and Laboratory Standards Institute (CLSI) breakpoints for viridans group streptococci. All isolates were susceptible to vancomycin: G. adiacens was more susceptible to penicillin and ampicillin than A. defectiva (22% versus 0% and 67% versus 33%) but less susceptible to ceftriaxone and daptomycin (56% versus 83% and 11% versus 50%). HLDR developed in both A. defectiva (33%) and G. adiacens (78%) after 24 h of exposure to daptomycin. Combination therapy did not prevent the development of daptomycin resistance with ampicillin (2/3 strains), gentamicin (2/3 strains), ceftriaxone (2/3 strains), or ceftaroline (2/3 strains). Once developed, HLDR was stable for a prolonged time (>3weeks) in G. adiacens, whereas in A. defectiva, HLDR reversed to the baseline MIC at day 10. This study is the first to demonstrate rapid HLDR development in Abiotrophia and Granulicatella species in vitro. Resistance was stable, and most combination therapies did not prevent it.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available